Stem cells in melanoma development
- PMID: 19095348
- PMCID: PMC3405359
- DOI: 10.1016/j.canlet.2008.10.039
Stem cells in melanoma development
Abstract
Cutaneous melanoma is a significant health problem worldwide. Available treatments can induce objective tumor regression in a small percent of patients, but these responses are not always associated with improved long-term survival. The resistance of melanoma to therapy and its predestined recurrence are related to the genetic heterogeneity and genomic instability of the tumor. For many years these genetic alterations were thought to be linked to the accumulation of random mutations in functionally differentiated cells which transform them into malignant cells that have lost their ability to differentiate and have acquired drug resistance. In the last few years it has been largely demonstrated that melanoma as other solid tumors contains a subpopulation of cells (CSCs) considered the source of the primary tumor mass, of new tumor nodules and responsible for drug resistance and cancer recurrence. In this review, we provide an overview of findings and advances in CSCs research that are relevant to the initiation, natural history, and the response to treatment of malignant melanoma.
Figures
Similar articles
-
Cancer stem cells and human malignant melanoma.Pigment Cell Melanoma Res. 2008 Feb;21(1):39-55. doi: 10.1111/j.1755-148X.2007.00427.x. Pigment Cell Melanoma Res. 2008. PMID: 18353142 Free PMC article. Review.
-
Nevi and Melanoma.Hematol Oncol Clin North Am. 2024 Oct;38(5):939-952. doi: 10.1016/j.hoc.2024.05.005. Epub 2024 Jun 15. Hematol Oncol Clin North Am. 2024. PMID: 38880666 Review.
-
Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.Arch Pathol Lab Med. 2010 Dec;134(12):1740-9. doi: 10.5858/2009-0418-RAR.1. Arch Pathol Lab Med. 2010. PMID: 21128770 Free PMC article. Review.
-
MITF pathway mutations in melanoma.Pigment Cell Melanoma Res. 2009 Aug;22(4):376-7. doi: 10.1111/j.1755-148X.2009.00599.x. Epub 2009 Jun 25. Pigment Cell Melanoma Res. 2009. PMID: 19558635 No abstract available.
-
Molecular pathogenesis of cutaneous melanocytic neoplasms.Annu Rev Pathol. 2009;4:551-79. doi: 10.1146/annurev.pathol.3.121806.151541. Annu Rev Pathol. 2009. PMID: 19400696 Review.
Cited by
-
Melanocortin-1 Receptor-Targeting Ultrasmall Silica Nanoparticles for Dual-Modality Human Melanoma Imaging.ACS Appl Mater Interfaces. 2018 Feb 7;10(5):4379-4393. doi: 10.1021/acsami.7b14362. Epub 2018 Jan 24. ACS Appl Mater Interfaces. 2018. PMID: 29058865 Free PMC article.
-
Generation of human melanocytes from induced pluripotent stem cells.PLoS One. 2011 Jan 13;6(1):e16182. doi: 10.1371/journal.pone.0016182. PLoS One. 2011. PMID: 21249204 Free PMC article.
-
Dormancy of metastatic melanoma.Pigment Cell Melanoma Res. 2010 Feb;23(1):41-56. doi: 10.1111/j.1755-148X.2009.00647.x. Epub 2009 Oct 19. Pigment Cell Melanoma Res. 2010. PMID: 19843243 Free PMC article. Review.
-
Characterization of a new human melanoma cell line with CD133 expression.Hum Cell. 2012 Jun;25(2):61-7. doi: 10.1007/s13577-011-0027-y. Epub 2012 Apr 13. Hum Cell. 2012. PMID: 22529031
References
-
- Beddingfield FC., III The melanoma epidemic: res ipsa loquitur. Oncologist. 2003;8:459–465. - PubMed
-
- Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, Smith K, Orlow I, Panageas K, Chapman PB. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol. 2008;26:2299–2304. - PubMed
-
- Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346–2357. - PMC - PubMed
-
- Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical